Insights

Riding the Oral GLP-1 Wave: CDMOs and Orally Administered GLP-1s

As more innovators look to develop orally administered GLP-1s further demand will be placed onto CDMOs to provide the expertise and capabilities needed to support the next generation of these drugs.
April 29, 2025

Building Strategic Partnerships Through Integrated CRDMO Services

Dr. Jim Li, President of CMC Solutions at BioDuro recently had the pleasure to sit down with the Pharma Source team to discuss how we build strategic partnerships through our integrated CRDMO Services.
April 18, 2025

BioDuro: Exploring Cutting-Edge Tech for More Reliable Formulations

The development of enhanced drug formulations requires an in-depth, data-driven understanding of Active Pharmaceutical Ingredients’ (APIs) physicochemical properties and their behavior in vivo. At BioDuro, formulation challenges such as poor solubility, stability, and bioavailability are addressed by systematically analyzing key characteristics of the API and the target patient population, explains Dr. Yuan Yang, Senior Scientist III, Formulation Development, BioDuro. A scientific approach that balances the inherent risk of formulation complexity with the practical needs of the drug product is critical for success.
April 07, 2025

Endpoints News Drug Discovery Day – Panel Discussion: Bridging the Chasm Between Discovery and Development

During the 2025 Endpoints News Drug Discovery Day, BioDuro’s Chief Scientific Officer Dr. Subas Sakya joined a distinguished panel discussion alongside other industry leaders to share key insights on accelerating and streamlining the discovery of both small molecules and biologics. This conversation explored the critical transition from discovery to development—one of the most challenging phases in drug innovation.
March 05, 2025

Fierce Pharma JPM Week – Interview: How Does the CRDMO Model Accelerate New Drug Development?

During 2025 Fierce Pharma JPM Week, Dr. Armin Spura, CEO of BioDuro was interviewed by Dr. Kurt Nielsen (Managing Partner, Expert Insights Consulting) as part of the Fierce Pharma fire-side chat serie
February 13, 2025

Patient Centric Dose Design to Drive Better Outcome

In the rapidly evolving pharmaceutical industry, the focus on patient-centric approaches is gaining significant momentum. Bhavishya Mittal, Ph.D., VP, Product Development and Manufacturing of BioDuro, recently shared his insights on the importance of patient-centric designs in driving better outcomes for oral solid dose (OSD) development in the January/February 2025 issue of Tablets & Capsules magazine. His perspectives highlight a critical shift in how pharmaceutical companies should approach drug development to improve patient adherence and overall healthcare outcomes.
February 10, 2025

Uncovering the CRDMO Advantage in Drug Development 

Bringing a new drug to market is always complicated, especially when working with multiple outsourcing partners. As a result, we are seeing a shift towards integrated CROs and CDMOs, which can offer e
January 19, 2025

How Can an Integrated CRDMO Help Accelerate Drug Development?

Kevin Li, Chief Marketing Officer of BioDuro-Sundia, sat down with Pharmaceutical Technology at CPHI 2024 in Milan to discuss how integrated CRDMO services can expedite the development of new drugs for biotechnology companies and start-ups.
October 30, 2024
Total 24 123
✉️Contact Us
We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all